Pharmaceuticals, Biotechnology and Life Sciences
Moderna has received FDA’s fast track designation for mRNA-1273 vaccine against the novel coronavirus, with finalizing protocol for Phase 3 study of mRNA-1273, expected to begin in early summer of 2020.
Moderna has engaged with Lonza to work on its novel coronavirus vaccine, with a goal to enable manufacturing of up to 1 billion doses per year, noting that technology transfer is expected to begin in June 2020.
Moderna has submitted IND to USFDA for 600 participant Phase 2 study to continue from ongoing NIH-led Phase 1 study, as planning underway for Phase 3 study expected to begin in the fall of 2020.
mRNA-1273 delivered from Company’s cGMP facility in 42 days from sequence selection CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a clinical…
Phase 2 CMV vaccine dose-confirmation study more than sixty percent enrolled mRNA-1189 to prevent infectious mononucleosis and Epstein-Barr virus (EBV)…
mRNA-3704 is Moderna’s first rare disease program to enter clinical studies CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a clinical stage…
Moderna recieved second rare disease program to receive Fast Track designation with mRNA-3927, which uses the same proprietary LNP formulation as…
mRNA-1944 successfully encoded for functional antibody (CHKV-24) in humans at all dose levels tested (0.1, 0.3 and 0.6 mg/kg) Antibody…
Vaccination immunized seronegative participants to levels consistent with or above seropositive titers and boosted baseline titers in seropositive participants Vaccine…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create…